Belmonte E, Bernardo A. 18 médicos recibieron más de 50.000 euros cada uno de una sola farmacéutica en 2017 . eldiario.es 2018:10 de octubre. [Ref.ID 102835]

Álvarez del Vayo M. Las asociaciones de pacientes recibieron casi seis millones de euros de la industria farmacéutica en 2016. CIVIO Medicamentalia 2018:19 de abril. [Ref.ID 102833]

Moore TJ, Hanzhe Z, Anderson G, Alexander C. Estimated costs of pivotal trials for novel therapeutic agents approved by the US Food and Drug Administration, 2015-2016. JAMA Intern Med 2018:24 de septiembre. [Ref.ID 102831]

Huang W-Y, Singer DE, Wu J-L, Chiang C-E, Weng H-H, Lee M, Ovbiagele B. Association of intracranial hemorrhage risk with non–vitamin K antagonist oral anticoagulant use vs aspirin use. A systematic review and meta-analysis. JAMA Neurology 2018:13 de agosto. [Ref.ID 102795]

Mitchell AP, Winn AN, Dusetzina SB. Pharmaceutical industry payments and oncologists’selection of targeted cancer therapies in Medicare beneficiaries. JAMA Intern Med 2018;178:junio. [Ref.ID 102773]

Anónimo. Inotuzumab ozogamicine et leucémie aiguë lymphoblastique chez les adultes. Prescrire 2018;38:494-9. [Ref.ID 102757]

Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ 2018;361:4 de julio. [Ref.ID 102751]

Anónimo. Novartis, Gilead CAR-T therapies both gain European panel recommendation. DIA Daily 2018:2. [Ref.ID 102703]

Montané E, Arellano AL, Sanz Y, Roca J, Farré M. Drug-related deaths in hospital inpatients: A retrospective cohort study. Br J Clin Pharmacol 2018;84:marzo. [Ref.ID 102649]

Adderley NJ, Nirantharakumar K, Marshall T. Risk of stroke and transient ischaemic attack in patients with a diagnosis of resolved atrial fibrillation: retrospective cohort studies. BMJ 2018;360:9 de mayo. [Ref.ID 102644]

Ross JS, Krumholz HM, Hines Jr HH. Bringing Vioxx back to market. BMJ 2018;360:k242. [Ref.ID 102639]

Lyman GH, Zon R, Harvey RD, Schilsky RL. Rationale, opportunities, and reality of biosimilar medications. N Engl J Med 2018;378:24 de mayo. [Ref.ID 102636]

Patel TK, Patel TB. Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis. Eur J Clin Pharmacol 2018;74:junio. [Ref.ID 102626]

Anónimo. Edoxaban: Interstitial lung disease. Japan . WHO Drug Information 2018;32:18. [Ref.ID 102620]

Hart RG, Sharma M, Mundl H, Kasner SE, Bagdiwala SI, Berkowitz SD, Swaminathan B, Lavados P, Wang Y, Davalos A, Shamalov N, Mikulik R, Cunha L, Lindgren A, Arauz A, Lang W, Czlonskowska A, Eckstein J, Gagliardi RJ, Amarenco P, Ameriso SF, Tatlisumak T, Veltkamp R, Hankey GJ, Toni D, Bereczki D, Uchiyama S, Ntaios G, Yoon BW, Brouns R, Endres M, Muir KW, Bornstein N, Ozturk S, O'Donnell MJ, De Vries Basson MM, Pare G, Pater C, Kirsch B, Sheridan P, Peters G, Weitz JI, Peacock WF, Shoamanesh A, Benavente OR, Joyner C, Themeles E, Connolly SJ, NAVIGATE ESUS Investigators. Ribaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 2018;378:2191-201. [Ref.ID 102610]

Anónimo. Blinatumomab et leucémie aiguë lymphoblastique chez les adultes. Prescrire 2018;38:97-9. [Ref.ID 102582]

Anónimo. Ixazomib et myélome multiple en echec. Prescrire 2018;38:95-7. [Ref.ID 102581]

Dekkers T, Lafeber M, Kramers C. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2018;378:1 de febrero. [Ref.ID 102523]

Wang X, Karnieg T. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2018;378:1 de febrero. [Ref.ID 102522]

Thayer K. Synthetic pot warning issued as number of users experiencing severe bleeding jumps to 32. Chicago Tribune 2018:1. [Ref.ID 102490]